Search

Your search keyword '"Soni, Amy"' showing total 15 results
Start Over Author "Soni, Amy"
15 results on '"Soni, Amy"'

1. Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia

Author

Hamadeh, Issam S., primary, Patel, Jai N., additional, Jacobs, Ryan, additional, Zeng, Hang, additional, He, Jiaxian, additional, Hu, Bei, additional, Moyo, Tamara Kay, additional, Soni, Amy, additional, Park, Steven, additional, Copelan, Ed, additional, Avalos, Belinda, additional, Hamilton, Alicia, additional, Steuerwald, Nury, additional, and Ghosh, Nilanjan, additional

Published
2023
Full Text
View/download PDF

2. Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)

Author

Chojecki, Aleksander L., primary, DiSogra, Kristyn Y., additional, Arnall, Justin, additional, Cowgill, Nicole, additional, Soni, Amy, additional, Packman, Charles H., additional, Sanikommu, Srinivasa Reddy, additional, Shah, Nilay A., additional, Ragon, Brittany K., additional, Knight, Thomas G., additional, Ai, Jing, additional, Avalos, Belinda R., additional, Copelan, Edward A., additional, and Grunwald, Michael R., additional

Published
2022
Full Text
View/download PDF

3. Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients

Author

Matuszfisher, Ashley, primary, Bose, Rupali, additional, Boselli, Danielle, additional, Magee, Gray, additional, Chen, Tommy, additional, Hu, Bei, additional, Moyo, Tamara K., additional, Soni, Amy, additional, Park, Steven I., additional, Copelan, Edward A., additional, Avalos, Belinda, additional, Symanowski, James T, additional, Raghavan, Derek, additional, Jacobs, Ryan, additional, and Ghosh, Nilanjan, additional

Published
2021
Full Text
View/download PDF

6. Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B‐cell lymphoma

Author

Hu, Bei, primary, Boselli, Danielle, additional, Pye, Lisa M., additional, Chen, Tommy, additional, Bose, Rupali, additional, Symanowski, James T., additional, Blackley, Kris, additional, Moyo, Tamara K., additional, Jacobs, Ryan, additional, Park, Steven I., additional, Soni, Amy, additional, Avalos, Belinda R., additional, Copelan, Edward A., additional, Raghavan, Derek, additional, and Ghosh, Nilanjan, additional

Published
2021
Full Text
View/download PDF

8. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B‐cell lymphoma, leg type.

Author

Moore, Donald C., Soni, Amy C., Hu, Bei, Smith, Elton T., Levine, Jonathan, Moyo, Tamara K., Jacobs, Ryan, Ghosh, Nilanjan, and Park, Steven I.

Subjects
*DIFFUSE large B-cell lymphomas, *LENALIDOMIDE, *RITUXIMAB, *MYELOID differentiation factor 88
Abstract

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is an exceedingly rare extra-nodal variant of diffuse large B-cell lymphoma (DLBCL) with an aggressive natural history that often manifests as red cutaneous tumour lesions on the lower extremities. Additionally, with the chemoresistant nature of PCDLBCL-LT and the relatively poor prognosis, many patients experience disease relapse and thus, novel treatment paradigms are needed for salvage therapy. PET/CT 13 months after starting therapy shows continued CR, and the patient remains in remission clinically at 20 months. After four cycles of therapy, an interim PET/CT scan demonstrated a CR with no hypermetabolic uptake to indicate active, recurrent, or metastatic disease. [Extracted from the article]

Published
2022
Full Text
View/download PDF

9. Outcomes in minority patients (pt) with aggressive B cell lymphoma (BCL) if optimally managed with equal access to care and nurse navigation (NN).

Author

Hu, Bei, primary, Chen, Tommy, additional, Boselli, Danielle, additional, Pye, Lisa, additional, Bose, Rupali, additional, Raghavan, Derek, additional, Symanowski, James Thomas, additional, Blackley, Kris, additional, Moyo, Tamara Kay, additional, Jacobs, Ryan, additional, Park, Steven, additional, Soni, Amy, additional, Avalos, Belinda, additional, Copelan, Edward Alan, additional, and Ghosh, Nilanjan, additional

Published
2020
Full Text
View/download PDF

15. Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers.

Author

Soni A, Aspinall SL, Zhao X, Good CB, Cunningham FE, Chatta G, Passero V, and Smith KJ

Subjects
Aged, Antimetabolites, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic economics, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Chemotherapy, Adjuvant economics, Cohort Studies, Colonic Neoplasms epidemiology, Female, Fluorouracil administration & dosage, Fluorouracil economics, Humans, Leucovorin administration & dosage, Leucovorin economics, Male, Middle Aged, Neoplasm Staging economics, Retrospective Studies, Treatment Outcome, United States epidemiology, Veterans, Antineoplastic Combined Chemotherapy Protocols economics, Colonic Neoplasms drug therapy, Colonic Neoplasms economics, Cost-Benefit Analysis methods, Hospitals, Veterans economics, United States Department of Veterans Affairs economics
Abstract

The objective of this study was to evaluate the real-world cost effectiveness of adjuvant stage III colon cancer chemotherapy regimens, given that previous analyses have been based on data from clinical trials. The study was designed using integrated decision tree and Markov model, which was developed to evaluate the cost effectiveness of 5-fluorouracil/leucovorin (5-FU/LV), capecitabine, and the combination of each with oxaliplatin. The analysis was performed from a US Veterans Affairs perspective via retrospectively collected data, over a 5-year model time horizon. Outcome and cost data were used to calculate cost per quality adjusted life year (QALY), and one-way and probabilistic sensitivity analyses were performed. In the base case analysis, capecitabine and capecitabine plus oxaliplatin both cost more and were less effective than other regimens, and 5-FU/LV plus oxaliplatin, compared to 5-FU/LV alone, resulted in a cost of $25,997 per QALY gained. Model results were generally robust to parameter variation. Capecitabine plus oxaliplatin could be economically reasonable if full dosing occurred ≥76% of the time (base case 42%). In a real-world setting, the addition of oxaliplatin to 5-FU/LV is more effective but also more costly than 5-FU/LV alone. If full dosing of capecitabine-containing regimens can be assured, they may also be cost-effective strategies.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results